Therapeutic bacteriophage compositions
Inventors
Shaw, Karen Joy • MORALES, Sandra P. • MEARNS, Gillian • RANKIN, Deborah A. • SMREKAR, Frenk
Assignees
Publication Number
US-11253557-B2
Publication Date
2022-02-22
Expiration Date
2036-08-15
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof, use of the same for medical or non-medical applications, kits, bandage, and wound dressing comprising the same.
Core Innovation
The invention provides a bacteriophage composition comprising one or more, preferably at least two, bacteriophages selected from Sa87, J-Sa36, Sa83, J-Sa37, or mutants thereof. These bacteriophages, either alone or in specific combinations, are utilized to target Staphylococcus aureus, including methicillin-resistant strains (MRSA). The composition is designed for use in both medical and non-medical applications, and may include additional bacteriophages, antibiotics, or carriers as appropriate.
A significant problem addressed by the invention is the urgent need for new treatments for bacterial infections, especially due to the rising resistance of human pathogens to antibiotics. The invention is intended to circumvent traditional mechanisms of antibiotic resistance, be effective against biofilms, and avoid disrupting the native gut flora, thereby providing an alternative or complementary therapeutic option to conventional antibiotics.
The bacteriophage composition is particularly advantageous for treating pulmonary bacterial infections, where the infection comprises Staphylococcus aureus. Methods for using the composition include administering it as a medicament, either alone or with antibiotics, and applying it topically, for example, as part of wound dressings or bandages. Kits containing the composition and instructions for use are also disclosed, supporting precise and effective therapeutic use.
Notably, the invention identifies that a combination of Sa87, J-Sa36, and Sa83 (excluding J-Sa37) results in reduced bacteriophage antagonism and decreases the development of resistance in target bacteria, thus improving therapeutic efficacy. This composition can be provided in various formulations suitable for different routes of administration, such as nasal, oral, or pulmonary, and may be used as a disinfectant for surfaces including medical equipment and skin.
Claims Coverage
The patent contains several independent claims outlining distinct inventive features related to bacteriophage compositions, their formulation, dosage, and kits.
Bacteriophage composition with at least two selected bacteriophages
A composition comprising at least two bacteriophages selected from Sa87, J-Sa36, and Sa83.
Bacteriophage composition consisting essentially of three defined bacteriophages
A composition consisting essentially of Sa87, J-Sa36, and Sa83.
Composition comprising two or more purified bacteriophage populations selected from Sa87, J-Sa36, and Sa83
A composition comprising two or more purified bacteriophage populations selected from Sa87, J-Sa36, and Sa83.
Kit comprising bacteriophage composition and instructions for use
A kit comprising a bacteriophage composition according to claim 1 and instructions for use.
The claims primarily cover defined compositions of selected purified bacteriophages, their formulation and combination with other agents, specific dosage ranges, and kits for administration and instruction.
Stated Advantages
Provides effective alternative treatments for infections caused by antibiotic-resistant Staphylococcus aureus, including MRSA.
Demonstrates improved therapeutic efficacy and reduced development of bacterial resistance compared to certain other phage combinations.
Exhibits reduced bacteriophage antagonism, leading to enhanced efficacy and stability of bacteriophage activity.
Is efficacious against a broad spectrum of Staphylococcus aureus strains.
Shows clinical efficacy in the treatment of Staphylococcus aureus pulmonary infections.
A combination with antibiotics can provide enhanced, sometimes synergistic, therapeutic effects.
Documented Applications
Treatment of pulmonary bacterial infections, particularly those caused by Staphylococcus aureus.
Use as a medicament for treating Staphylococcus aureus infections in mammals, including humans.
Application in kits comprising the bacteriophage composition and instructions for use in medicine.
Application as a topical disinfectant composition, including in bandages or wound dressings for inhibiting or treating bacteria.
Non-medical applications such as food hygiene, agriculture or crop protection, and environmental hygiene.
Use to kill Staphylococcus aureus bacteria on surfaces, including skin, medical equipment, bedding, furniture, walls, and floors.
Interested in licensing this patent?